Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 17990236.
- Also identified by PMC identifier 3687541.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We examined the incidence of and risk factors for tuberculosis during the first year of highly active antiretroviral therapy in low-income (4540 patients) and high-income (22,217 patients) countries. Although incidence was much higher in low-income countries, the reduction in the incidence of tuberculosis associated with highly active antiretroviral therapy was similar: the rate ratio for months 7-12 versus months 1-3 was 0.48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings.
Medical subject headings
- Anti-Retroviral Agents
- Developed Countries
- Developing Countries
- HIV Infections
- Tuberculosis